Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

IMS Health Downgraded Following Weak Second-Quarter Report

By Pharmaceutical Processing | July 24, 2009

NEW YORK (AP) — Analysts cut their ratings on IMS Health Inc. Friday after the pharmaceutical market researcher lowered its expectations and said it will restructure and eliminate jobs following a weak second-quarter report. The Norwalk, Conn., company plans to trim 850 jobs and focus on higher growth regions and markets. IMS’s quarterly profit and revenue were both below analyst expectations, and the company reduced its profit and revenue forecasts for the full year. IMS forecast a charge of $110 million to $120 million in the third quarter from the restructuring, and said it will save $85 million a year starting in 2011. Robert W. Baird analyst Eric Coldwell downgraded the stock to “Underperform” from “Neutral” based on the results. He said the company will probably not report any profit growth in 2010 in addition to its lower expectations for 2009. “The client environment is weakening, another 18-month transition period is upon us with a massive global restructuring, and we see limited avenues for growth in years ahead,” he said. Coldwell said IMS shares did fairly well on Thursday despite the news, because the company said its adjusted profit was 44 cents per share — six cents per share ahead of analysts’ estimates. But Coldwell said IMS’s adjusted operating profit was really 30 cents per share, because the company posted a gain of 14 cents from a tax accrual reversal. He cut his price target to $11 per share from $14. Thomas Weisel Partners analyst Steven Halper downgraded the shares to “Market Perform” from “Overweight,” writing in a client note, “It appears that spending by IMS’s clients has declined while sales cycles have elongated.” IMS stock slid 5.9 percent to $12.14 Thursday. In premarket trading, shares gave up another 41 cents, or 3.4 percent, to $11.73.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE